Results 141 to 150 of about 2,146 (159)

Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies

European Journal of Haematology, 2022
Su-Peng Yeh, Joo-Seop Chung, Jun Ho Jang   +2 more
exaly  

Ravulizumab in neuer Konzentration zugelassen

InFo Hämatologie + Onkologie, 2021
openaire   +1 more source

Ravulizumab for COVID-19 Kidney Injury

Journal of the American Society of Nephrology, 2022
Aliza Anwar Memon, Hasban Ahmed, Andrew M. Siedlecki   +2 more
openaire   +1 more source

Ravulizumab effective in AQP4+ NMOSD

Medicom Conference Report AAN 2023, 2023
openaire   +1 more source

A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome

Journal of Medical Economics, 2020
Evan Popoff, Ioannis Tomazos
exaly  

Keine komplementvermittelten Durchbruchhämolysen mit Ravulizumab

Transfusionsmedizin, 2021
openaire   +1 more source

Meningococcal vaccine conjugate/ravulizumab

Reactions Weekly, 2019
openaire   +1 more source

Eculizumab/Ravulizumab

Reactions Weekly
openaire   +1 more source

Plasma/Ravulizumab

Reactions Weekly
openaire   +1 more source

Summary of opinion: Ultomiris,ravulizumab

Case Medical Research, 2019
openaire   +2 more sources